论文部分内容阅读
采用体外基因扩增多聚酶链反应（ＰＣＲ），研究了３６例非霍奇金淋巴瘤（ＮＨＬ）及１９例淋巴结反应性增生（ＲＨ）患者的免疫球蛋白重链（ＩｇＨ）和Ｔ细胞受体γ（ＴＣＲγ）基因重排。结果３６例ＮＨＬ中，３４例出现克隆性ＩｇＨ和ＴＣＲγ基因重排（９４．４％），其中９１％的Ｂ－ＮＨＬ出现ＩｇＨ基因重排，９５％的Ｔ－ＮＨＬ出现ＴＣＲγ基因重排。１９例ＲＨ患者，１４例上述基因保持胚系状态，５例检测到克隆性ＩｇＨ或ＴＣＲγ基因重排。此５例随后的临床表现及治疗反应，均支持恶性淋巴瘤的诊断。表明抗原受体基因重排是淋巴瘤分子水平可靠的克隆性标记，有助于在基因水平确定肿瘤细胞的来源及其分化阶段，尤其在良、恶性淋巴结增殖性疾病的鉴别诊断方面，具有重要的临床应用价值。
In vitro gene amplification polymerase chain reaction (PCR) was used to study immunoglobulin heavy chain (IgH) and T cell receptors in 36 patients with non-Hodgkin’s lymphoma (NHL) and 19 patients with reactive lymph node hyperplasia (RH). γ (TCRγ) gene rearrangements. Results Of the 36 NHLs, 34 cases had clonal IgH and TCRγ gene rearrangement (94.4%), of which 91% of B-NHL had IgH gene rearrangement and 95% of T-NHL had TCRγ gene rearrangement. In 19 patients with RH, 14 of the above genes maintained the germline status, and 5 cases detected clonal IgH or TCRγ gene rearrangement. The subsequent clinical manifestations and treatment responses of these 5 cases all supported the diagnosis of malignant lymphoma. It indicates that the rearrangement of antigen receptor gene is a reliable clonal marker at the molecular level of lymphoma, which helps to determine the source and differentiation stage of tumor cells at the gene level, especially in the differential diagnosis of benign and malignant lymph node proliferative diseases. The clinical application value.